28987-44-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Ethoxy-4-fluoro-1-nitrobenzene is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique molecular structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicine.
Used in Agrochemical Industry:
In the agrochemical sector, 2-ethoxy-4-fluoro-1-nitrobenzene is utilized as a precursor in the production of certain pesticides and herbicides. Its chemical properties enable the creation of effective agents for crop protection and weed control.
Used in Dye Industry:
2-ETHOXY-4-FLUORO-1-NITROBENZENE also finds application in the dye industry, where it is employed in the manufacturing process of various dyes. Its chemical reactivity and stability contribute to the production of dyes with specific color characteristics and properties.

InChI:InChI=1/C8H8FNO3/c1-2-13-8-5-6(9)3-4-7(8)10(11)12/h3-5H,2H2,1H3

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 446-35-5 2,4-Difluoronitrobenzene 
• 446-36-6 5-fluoro-2-nitrophenol 
• 1972-28-7 diethylazodicarboxylate 
• 75-03-6 ethyl iodide 
• 64-17-5 ethanol 
• 74-96-4 ethyl bromide 
• 141-52-6 sodium ethanolate 
• 917-58-8 potassium ethoxide 

Downstream Products

• 178993-28-7 2-ethoxy-4-fluorobenzenamine 
• 1124330-03-5 1-(3-ethoxy-4-nitrophenyl)-N,N-dimethylpiperidin-4-amine 
• 1124330-06-8 2-(3-ethoxy-4-nitro-phenoxy)-N,N-dimethyl-ethanamine 
• 1124330-01-3 1-(3-ethoxy-4-nitro-phenyl)-4-methyl-1,4-diazepane 
• 951667-63-3 5-(3-Ethoxy-4-nitro-phenoxy)-2-(toluene-4-sulfonyl-amino)-benzoic acid methyl ester 
• 64635-54-7 3-ethoxy-4-nitrophenol 

Relevant academic research and scientific papers

Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker

Due to the limitations of existing medications, there is a critical need for new drugs to treat visceral leishmaniasis. Since arylimidamides and antifungal azoles both show oral activity in murine visceral leishmaniasis models, a molecular hybridization approach was employed where arylimidamide and azole groups were separated by phenoxyalkyl linkers in an attempt to capitalize on the favorable antileishmanial properties of both series. Among the target compounds synthesized, a greater antileishmanial potency against intracellular Leishmania donovani was observed as the linker length increased from two to eight carbons and when an imidazole ring was employed as the terminal group compared to a 1,2,4-triazole group. Compound 24c (N-(4-((8-(1H-imidazol-1-yl)octyl)oxy)-2-isopropoxyphenyl) picolinimidamide) displayed activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM. When tested in a murine visceral leishmaniasis model, compound 24c at a dose of 75 mg/kg/day p.o. for five consecutive days resulted in a modest 33% decrease in liver parasitemia compared to the control group, indicating that further optimization of these molecules is needed. While potent hybrid compounds bearing an imidazole terminal group were also strong inhibitors of recombinant CYP51 from L. donovani, as assessed by a fluorescence-based assay, additional targets are likely to play an important role in the antileishmanial action of these compounds.

Discovery and structure ? activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Internal tandem duplications of FLT3 (FLT3-ITD) occur in approximately 25% of all acute myeloid leukemia (AML) cases and confer a poor prognosis. Optimization of the screening hit 1 from our in-house compound library led to the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives as potent and selective FLT3-ITD inhibitors. Compounds 17 and 19 displayed potent FLT3-ITD activities both with IC50 values of 0.4 nM and excellent antiproliferative activities against AML cell lines. Especially, compounds 17 and 19 inhibited the quizartinib resistance- conferring mutations, FLT3D835Y, both with IC50 values of 0.3 nM. Moreover, western blot analysis indicated that compounds 17 and 19 potently inhibited the phosphorylation of FLT3 and attenuated downstream signaling in AML cells. These results indicated that pyrazolo[1,5-a]pyrimidine derivatives could be promising FLT3-ITD inhibitors for the treatment AML.

A class of FLT3 kinase inhibitors, preparation and application thereof

The invention relates to a class of FLT3 kinase inhibitors, preparation and application thereof, wherein specifically the compound has a structure represented by a formula (I), and all groups and substituents are defined in the specification. The invention also discloses a preparation method of the compound, and application of the compound in inhibition of FLT3.

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS

The present invention relates to 2,4-diaminopyrimidines and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for the treatment of disease states,

PYRIMIDINE DERIVATIVE AND USE THEREOF

The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.

Substituted indole or indole pyrimidine derivative as well as preparation method and application of substituted indole or indole pyrimidine derivative

The invention relates to a substituted indole or an indole pyrimidine derivative as well as a preparation method, a pharmaceutical composition and application of the substituted indole or the indole pyrimidine derivative, in particular relates to a compou

An arylamino pyrimidine compound and crystals of salts of the compound

The invention provides an arylamino pyrimidine compound and crystals of salts thereof, belongs to the technical fields of medicines and chemical engineering, and particularly relates to N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-ethyoxyl-5-(4-(1-methy

Design and Synthesis of Highly Active Peroxisome Proliferator-Activated Receptor (PPAR) β/δ Inverse Agonists with Prolonged Cellular Activity

Based on 3-(((4-(hexylamino)-2-methoxyphenyl)amino)sulfonyl)-2-thiophenecarboxylic acid methyl ester (ST247, compound 2), a recently described peroxisome proliferator-activated receptor (PPAR)β/δ-selective inverse agonist, we designed and synthesized a se

Pyrimidine or triazine derivative, and preparation method and use thereof

The invention relates to an arylaminopyrimidine or triazine derivative, and a preparation method, a medicinal composition and a use thereof, and concretely relates to a compound represented by formula I, or a pharmaceutically acceptable salt or a solvate thereof. In the formula I, R1 to R7, X and Y are defined in the description and claims. The invention also relates to a preparation method of the compound of formula I, the medicinal composition containing the compound, and the pharmacy use of the compound and the medicinal composition. The compound of formula I is an effective tyrosine kinase irreversible inhibitor, and especially has a strong inhibition effect on EGFR-T790M drug-resistant tumors.